DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for malignant breast myoepithelioma — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMalignant breast myoepithelioma maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for malignant breast myoepithelioma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
phosphoinositide-3-kinase regulatory subunit 1 (PIK3R1) — PIK3R1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 1rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8W9A · 2.7 Å · ligand 6-chloranyl-3-[[(1R)-1-[2-(1,3-dihydropyrrolo[3,4-c]pyridin-2-yl)-3,6-dimethyl-4-oxidanylidene-quinazolin-8-yl]ethyl]amino]pyridine-2-carboxylic acid (UEX). Experimental structure, not a prediction.
What the evidence adds up to
A 73-year-old woman with epithelial-myoepithelial carcinoma of the left breast (malignant adenomyoepithelioma) had a tumour showing nests of neoplastic epithelium and myoepithelium with cytologic atypia, increased mitoses, and infiltrative growth. Mutational analysis found oncogenic driver mutations in HRAS and PIK3CA. At 29 months follow-up she had no evidence of recurrent or metastatic disease. This is a single case report.
A separate case describes a 42-year-old woman with a malignant myoepithelioma of the breast presenting as a 13.31 x 8.83 x 12.04 cm lobulated inhomogeneous hypoechoic tumour involving all quadrants. She received adjuvant radiation of 50 Gy in 25 fractions to the chest wall and axilla, followed by adjuvant chemotherapy with four cycles of Adriamycin and Cyclophosphamide and four cycles of paclitaxel. The authors state that early detection and a multimodality approach are usually required, but the abstract gives no survival or response data for this patient.
A third report, from soft tissue rather than breast, describes an 84-year-old man with a myoepithelial carcinoma combined with myoepithelioma in the right forearm. The authors note that myoepithelioma of soft tissue can progress to malignant myoepithelioma. No treatment outcome or follow-up duration is given.
Across these three case reports, no controlled trial data exist for malignant breast myoepithelioma. The only patient with reported follow-up (29 months, no recurrence) had a tumour with HRAS and PIK3CA mutations, but whether those mutations are targetable or prognostic in this disease is unknown. What is missing is any prospective trial, any standardised treatment protocol, any reliable estimate of response rates to chemotherapy or radiation, and any patient stratification by mutation or histology.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
International Journal of Surgical Pathology · 2018 · 31 citations
Mammary Epithelial-Myoepithelial Carcinoma: Report of a Case With <i>HRAS</i> and <i>PIK3CA</i> Mutations by Next-Generation Sequencing
AbstractWe present the case of a 73-year-old woman with an epithelial-myoepithelial carcinoma of the left breast (ie, malignant adenomyoepithelioma). In both the initial needle core biopsy and in the subsequently performed lumpectomy, the tumor consisted of nests of neoplastic epithelium and myoepithelium with cytologic atypia, increased mitoses, and infiltrative growth into the surrounding tissue. Mutational analysis showed oncogenic driver mutations in HRAS and PIK3CA. In this article, we describe an epithelial-myoepithelial carcinoma of the breast with focal metaplastic differentiation, an extremely rare entity, and report the results of targeted next-generation sequencing. Our patient has not shown any evidence of recurrent or metastatic disease at 29 months follow-up.
Journal of Medical Case Reports · 2014 · 12 citations · open access
Combined myoepithelial carcinoma and myoepithelioma in soft tissue: a case report and review of the literature
AbstractINTRODUCTION: Soft tissue myoepithelial carcinoma and myoepithelioma are rare entities, part of myoepithelial tumors. They were incorporated into the World Health Organization classification of soft tissue tumors in 2002. Here we present an exceptional case of myoepithelial carcinoma and myoepithelioma association. To the best of our knowledge, such an association has never been reported in the literature. CASE PRESENTATION: We report a case of myoepithelial carcinoma combined with myoepithelioma occurring in the soft tissue of the right forearm of an 84-year-old Arabian man. We describe the clinical, radiological and pathological features dominated by histological polymorphism. We will also describe the proposed histological criteria of malignancy and the major role of immunohistochemistry in positive and differential diagnosis. We finally mention the therapeutic arsenal available. CONCLUSION: Through this work, we report that myoepithelioma of soft tissue can progress to malignant myoepithelioma.
Zenodo (CERN European Organization for Nuclear Research) · 2024 · 0 citations · open access
A Case Report on Myoepithelial carcinoma of breast treated with Multi modality approach
AbstractBackground: Myoepithelial carcinomas are extremely rare in occurrence with limited number of published articles of malignant myoepitheliomas arising from the breast Case Report: A 42 year old female patient presented at an outside center with complaints of pain in left breast , sonomammogram was suggestive of lobulated inhomogenous hypoechoic tumor with smooth margins and multiple cystic areas within the tumor involving all quadrants of breast with size of 13.31X8.83X12.04cm.Patient received Adjuvant Radiation of 50Gy in 25 fractions to the chest wall and axilla and followed by Adjuvant Chemotherapy with four cycles of Adriamycin and Cyclophosphamide and four cycles of paclitaxel. Conclusion: Early detection and multimodality approach is usually required for the management of Myoepithelial carcinoma of Breast.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
